Strong Quarter for Medtronic (MDT) Drives Upward Revision in 2024 Financial Outlook
Image courtesy of 123rf.com

Strong Quarter for Medtronic (MDT) Drives Upward Revision in 2024 Financial Outlook

Medtronic plc (NYSE: MDT) reported strong third-quarter fiscal year 2024 results, with revenue of $8.1 billion, surpassing expectations.
Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, reported a solid third quarter for fiscal year 2024, demonstrating its commitment to innovation and growth across its diverse portfolio.

Medtronic’s financial results for the third quarter of fiscal year 2024 have been noteworthy, with the company reporting revenue of $8.1 billion, a 4.7% increase as reported and 4.6% on an organic basis. This growth reflects Medtronic’s continued momentum, driven by strong performances in Diabetes, Core Spine, Cardiac Surgery, Structural Heart, and Cardiac Pacing, as well as significant strength in international markets.

The company’s GAAP diluted earnings per share (EPS) stood at $0.99, with non-GAAP diluted EPS reaching $1.30. This solid financial performance underscores Medtronic’s ability to deliver on its commitments and drive growth across its key business areas.

Medtronic PLC Outperforms Expectations in Fiscal Q3

When comparing the actual financial outcomes to the expectations for the quarter, Medtronic has surpassed the anticipated EPS of $1.26 and revenue of $7.95 billion. The actual non-GAAP diluted EPS of $1.30 and revenue of $8.1 billion exceeded the forecasts. This outperformance is indicative of the company’s robust operational execution and its ability to capitalize on the growing demand for its innovative healthcare solutions globally.

Guidance

Medtronic has raised its full-year guidance for fiscal year 2024, reflecting the company’s confidence in its continued growth trajectory. The updated FY24 organic revenue growth guidance ranges from 4.75% to 5%, marking an increase from the prior guidance. Additionally, the company has elevated its FY24 diluted non-GAAP EPS guidance, now expecting it to fall between $5.19 and $5.21, reflecting both the third quarter’s outperformance and Medtronic’s optimistic outlook for the remainder of the fiscal year.

Disclaimer: The author does not hold or have a position in any securities discussed in the article.